Øystein Rekdal
Vermogen: 201 262 $ op 31-05-2026
Vermogen: 201 262 $ op 31-05-2026
Øystein Rekdal is the founder of Lytix Biopharma AS, serving as Chief Executive Officer & Media Relations Contact since 2019, founded in 2003.
Dr. Rekdal is a Professor at the University of Tromso.
Formerly, Dr. Rekdal worked as Director at Prophylix AS.
Education includes a doctorate from the University of Tromso.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LYTIX BIOPHARMA ASA 0,23% | 11-12-2025 | 176.179 ( 0,23% ) | 201 262 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| LYTIX BIOPHARMA ASA | Algemeen Directeur | 11-09-2019 |
University of Tromso
University of Tromso Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Bedrijven | Functie | Einde |
|---|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Provides prophylactic medicinal product for newborns | Directeur/Bestuurslid | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 3 |
|---|---|
University of Tromso
University of Tromso Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lytix Biopharma AS
Lytix Biopharma AS Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops novel cancer immunotherapies | Health Technology |
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Provides prophylactic medicinal product for newborns | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau